BioCryst Pharmaceuticals, Inc. (BMV:BCRX)

BioCryst Pharmaceuticals Statistics

Total Valuation

BMV:BCRX has a market cap or net worth of MXN 37.76 billion. The enterprise value is 41.24 billion.

Market Cap	37.76B
Enterprise Value	41.24B

Important Dates

The last earnings date was Thursday, February 26, 2026.

Earnings Date	Feb 26, 2026
Ex-Dividend Date	n/a

Share Statistics

Current Share Class	210.54M
Shares Outstanding	n/a
Shares Change (YoY)	+5.75%
Shares Change (QoQ)	-0.28%
Owned by Insiders (%)	0.98%
Owned by Institutions (%)	71.44%
Float	217.75M

Valuation Ratios

The trailing PE ratio is 7.95 and the forward PE ratio is 19.80.

PE Ratio	7.95
Forward PE	19.80
PS Ratio	2.40
PB Ratio	-17.60
P/TBV Ratio	n/a
P/FCF Ratio	6.08
P/OCF Ratio	6.04
PEG Ratio	n/a

Enterprise Valuation

The stock's EV/EBITDA ratio is 6.96, with an EV/FCF ratio of 6.64.

EV / Earnings	8.68
EV / Sales	2.74
EV / EBITDA	6.96
EV / EBIT	7.03
EV / FCF	6.64

Financial Position

The company has a current ratio of 2.06

Current Ratio	2.06
Quick Ratio	1.95
Debt / Equity	n/a
Debt / EBITDA	1.36
Debt / FCF	1.38
Interest Coverage	4.40

Financial Efficiency

Return on Equity (ROE)	n/a
Return on Assets (ROA)	43.22%
Return on Invested Capital (ROIC)	408.62%
Return on Capital Employed (ROCE)	109.18%
Weighted Average Cost of Capital (WACC)	n/a
Revenue Per Employee	27.15M
Profits Per Employee	8.19M
Employee Count	580
Asset Turnover	1.74
Inventory Turnover	26.83

Taxes

In the past 12 months, BMV:BCRX has paid 63.55 million in taxes.

Income Tax	63.55M
Effective Tax Rate	1.32%

Stock Price Statistics

The stock price has decreased by -23.87% in the last 52 weeks.

Beta (5Y)	n/a
52-Week Price Change	-23.87%
50-Day Moving Average	242.70
200-Day Moving Average	n/a
Relative Strength Index (RSI)	38.26
Average Volume (20 Days)	580

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	9.17

Income Statement

In the last 12 months, BMV:BCRX had revenue of MXN 15.75 billion and earned 4.75 billion in profits. Earnings per share was 21.78.

Revenue	15.75B
Gross Profit	12.49B
Operating Income	6.25B
Pretax Income	4.81B
Net Income	4.75B
EBITDA	6.28B
EBIT	6.25B
Earnings Per Share (EPS)	21.78

Balance Sheet

The company has 4.95 billion in cash and 8.59 billion in debt, with a net cash position of -3.65 billion.

Cash & Cash Equivalents	4.95B
Total Debt	8.59B
Net Cash	-3.65B
Net Cash Per Share	n/a
Equity (Book Value)	-2.15B
Book Value Per Share	-10.07
Working Capital	3.75B

Cash Flow

In the last 12 months, operating cash flow was 6.25 billion and capital expenditures -44.43 million, giving a free cash flow of 6.21 billion.

Operating Cash Flow	6.25B
Capital Expenditures	-44.43M
Free Cash Flow	6.21B
FCF Per Share	n/a

Margins

Gross margin is 79.32%, with operating and profit margins of 39.70% and 30.16%.

Gross Margin	79.32%
Operating Margin	39.70%
Pretax Margin	30.56%
Profit Margin	30.16%
EBITDA Margin	39.86%
EBIT Margin	39.70%
FCF Margin	39.42%

Dividends & Yields

BMV:BCRX does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-5.75%
Shareholder Yield	-5.75%
Earnings Yield	12.58%
FCF Yield	16.45%

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	n/a
Graham Upside	n/a

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

BMV:BCRX has an Altman Z-Score of 1.95 and a Piotroski F-Score of 6. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	1.95
Piotroski F-Score	6